Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04312113 · ClinicalTrials.gov registry record · Phase 1
Angiographic Delivery of AD-MSC for Ulcerative Colitis
A Phase 1 study of Ulcerative Colitis, sponsored by Mayo Clinic.
- Active
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT04312113 is a Phase 1 study of Ulcerative Colitis that is active but no longer recruiting, run by Mayo Clinic. The registered enrollment target is 20 participants, below the 2,057-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04312113, a Phase 1 study of Ulcerative Colitis, is active but no longer recruiting, sponsored by Mayo Clinic.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
Researchers are trying to determine the safety and feasibility of using an adipose derived mesenchymal stem cell (MSC) to treat people with Ulcerative Colitis.
Conditions Studied
Interventions
- DRUG Adipose derived, autologous mesenchymal stem cells
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2020-11-16 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04312113
The ClinicalTrials.gov registry entry for NCT04312113 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,057-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (99% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ulcerative Colitis appearing as the primary indexed condition, and to 1 intervention - of which Adipose derived, autologous mesenchymal stem cells is the first listed.
NCT04312113 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT04312113 about?
NCT04312113 is a clinical study titled "Angiographic Delivery of AD-MSC for Ulcerative Colitis". Researchers are trying to determine the safety and feasibility of using an adipose derived mesenchymal stem cell (MSC) to treat people with Ulcerative Colitis.
What is the current status of trial NCT04312113?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2020-11-16. Estimated completion is 2026-12.
What conditions does trial NCT04312113 study?
This clinical trial studies the following conditions: Ulcerative Colitis.
What interventions are being tested in trial NCT04312113?
The interventions under investigation include: Adipose derived, autologous mesenchymal stem cells (DRUG).
Who is sponsoring clinical trial NCT04312113?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04312113 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ulcerative Colitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Use of Butyrate Therapy in Pediatric Ulcerative Colitis
RECRUITING · Phase 1
-
R-3750 in Patients With Mild to Moderate Ulcerative Colitis
RECRUITING · Phase 1
-
Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy
RECRUITING · Phase 1
-
CP101 for the Treatment of Ulcerative Colitis
ACTIVE NOT RECRUITING · Phase 1
-
Safety, Tolerability, and Pharmacokinetics of Oral NX-13 in Active Ulcerative Colitis
COMPLETED · Phase 1
-
Safety and Pharmacokinetics Study of HE3286 in Patients With Active, Mild-to-Moderate Ulcerative Colitis
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.